<table border="1"><tr><th>Nom UICPA</th><td>N-(2-(4-(4-fluorobenzylcarbamoyl) -5-hydroxy-1-méthyl-6-oxo-1,6-dihydropyrimidin -2-yl)propan-2-yl)-5-méthyl -1,3,4-oxadiazole-2-carboxamide</td></tr><tr><th>N | o |  CAS</th><td>518048-05-0</td></tr><tr><th> N | o |  ECHA</th><td>100.124.631</td></tr><tr><th>Code ATC</th><td>J05 | AX08</td></tr><tr><th>PubChem</th><td>54671008</td></tr><tr><th>SMILES</th><td>Cc1nnc(o1)C(=O)NC(C)(C)C3=NC(C(=O)NCc2ccc(F)cc2)=C(O)C(=O)N3C | PubChem | , | vue 3D</td></tr><tr><th>InChI</th><td>InChI | vue 3D | InChI=1/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30) | InChIKey | CZFFBEXEKNGXKS-UHFFFAOYSA-N</td></tr><tr><th>Formule</th><td>C | 20 | H | 21 | FN | 6 | O | 5 | [Isomères]</td></tr><tr><th>Masse molaire</th><td>444,4163 ± 0,0202 g/mol | C 54,05 %, H 4,76 %, F 4,27 %, N 18,91 %, O 18 %,</td></tr><tr><th>Biodisponibilité</th><td>&quot;bonne&quot;</td></tr><tr><th>Classe thérapeutique</th><td>Antirétroviral : Inhibiteur d&#x27;intégrase</td></tr><tr><th>Voie d’administration</th><td>Orale</td></tr><tr><th>Grossesse</th><td>Contre-indiquée | (catégorie C)</td></tr><tr><th>Précautions</th><td>surveiller la créatine kinase</td></tr></table>